Scarica l'app Stockscreener
0.959
0.21%
0.002
Precedente Chiudi:
$0.957
Aprire:
$1.05
Volume 24 ore:
282.53K
Relative Volume:
1.71
Capitalizzazione di mercato:
$27.40M
Reddito:
$40.58M
Utile/perdita netta:
$-80.65M
Rapporto P/E:
-0.2879
EPS:
-3.331
Flusso di cassa netto:
$-8.11M
1 W Prestazione:
-3.13%
1M Prestazione:
-27.89%
6M Prestazione:
-44.24%
1 anno Prestazione:
-39.87%
Intervallo 1D:
$0.88
$1.05
Intervallo di 1 settimana:
$0.88
$1.149
Portata 52W:
$0.88
$4.35
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.95 | 27.60M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
426.25 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.64 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.72 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.49 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
296.93 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - Investing News Network
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity regains Nasdaq compliance after filing annual report By Investing.com - Investing.com South Africa
Celularity regains Nasdaq compliance after filing annual report - Investing.com
Nasdaq closes Celularity listing case after delayed 10-K filing - Stock Titan
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) - marketscreener.com
[10-K] Celularity Inc Files Annual Report - Stock Titan
NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal - Stock Titan
Celularity Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Celularity (CELU) Registration Filing Summary - Quartr
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
NEXGEL taps M&A veteran as CFO to steer Celularity integration - Stock Titan
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
Celularity receives Nasdaq notification - MSN
Celularity Inc (CELU) insider Form 3 details warrants and convertible notes - Stock Titan
Celularity Inc (CELU) insider lists warrant and note holdings - Stock Titan
Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3 - Stock Titan
CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%.Guidance Upgrade - Cổng thông tin điện tử Tỉnh Sơn La
Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower lossDistressed Pick - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELUW) Stock: Is It Breaking Uptrend Earnings ReportNCAV - Xã Thanh Hà
CELU (Celularity Inc.) Q3 2025 EPS beats analyst expectations, registers a small post-earnings stock dip.Secondary Offering - Xã Thanh Hà
Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Announces Closing of Transaction with NexGel - Investing News Network
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
NexGel Closes Celularity Biomaterials License Terms and Secures $6.9M Convertible Note Financing - TradingView
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
NexGel closes acquisition of products from Celularity - TipRanks
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Investing News Network
Nexgel new strategic partner, Sequence LifeScience, leads financing with $5.5 million to complete acquisition of Celularity degenerative disease segment - marketscreener.com
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks
NEXGEL closes Celularity biomaterials deal, raises $5.5 million - Investing.com
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™ - Bitget
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - The Manila Times
Celularity Inc. Announces Management Resignations - marketscreener.com
Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads - GlobeNewswire
Celularity Closes Transaction with NexGel to Monetize Biomaterials - Intellectia AI
NEXGEL, Inc. completed the acquisition of Portfolio of Commercial-stage Regenerative Biomaterial Products of Celularity Inc. for 15.8 million. - marketscreener.com
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - The Manila Times
Celularity receives Nasdaq notice for delayed annual report filing By Investing.com - Investing.com Australia
Celularity receives Nasdaq notice for delayed annual report filing - Investing.com
Celularity Receives Nasdaq Notice for Delayed Filing of 2025 Annual Report - geneonline.com
CELULARITY ANNOUNCES RECEIPT OF NASDAQ NOTICE REGARDING LATE FORM 10-K FILING - Moomoo
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):